Mitochondrial Disorder Aggravated by Metoprolol

Beta-adrenergic blocking agents or beta-blockers are a class of medications used to treat cardiac arrhythmias and systemic hypertension. In therapeutic dosages, they have known adverse outcomes that can include muscular fatigue and cramping, dizziness, and dyspnea. In patients with mitochondrial disease, these effects can be amplified. Previous case reports have been published in the adult population; however, their impact in pediatric patients has not been reported. We describe a pediatric patient with a mitochondrial disorder who developed respiratory distress after metoprolol was prescribed for hypertension. As the patient improved with discontinuation of medication and no alternative etiology was found for symptoms, we surmise that administration of metoprolol aggravated his mitochondrial dysfunction, thus worsening underlying chest wall weakness.

[1]  N. Khachapuridze,et al.  [MITOCHONDRIAL DYSFUNCTION: MODERN ASPECTS OF THERAPY (REVIEW)]. , 2015, Georgian medical news.

[2]  Marni J. Falk,et al.  Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society , 2014, Genetics in Medicine.

[3]  C. Schmidt Unraveling Environmental Effects on Mitochondria , 2010, Environmental Health Perspectives.

[4]  J. Finsterer,et al.  Drugs interfering with mitochondrial disorders , 2010, Drug and chemical toxicology.

[5]  M. Koenig Presentation and diagnosis of mitochondrial disorders in children. , 2008, Pediatric Neurology.

[6]  P. Bottoni,et al.  The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. , 2007, American journal of physiology. Cell physiology.

[7]  J. Finsterer,et al.  Mitochondrial Disorder Aggravated by Propranolol , 2006, Southern medical journal.

[8]  F. Bernier,et al.  Diagnostic criteria for respiratory chain disorders in adults and children , 2002, Neurology.

[9]  T. Kishi,et al.  Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. , 1977, Research communications in chemical pathology and pharmacology.

[10]  W. Blessing,et al.  MYOTONIA PRECIPITATED BY PROPRANOLOL THERAPY , 1977, The Lancet.

[11]  Y. Imai,et al.  Muscle cramps and elevated serum creatine phosphokinase levels induced by β-adrenoceptor blockers , 2004, European Journal of Clinical Pharmacology.